First Brands Group debt targeted by Apollo Global Management - report
VANCOUVER - Ondine Biomedical Inc. (AIM:OBI) announced Wednesday that its Steriwave nasal photodisinfection technology was highlighted on CNBC’s Worldwide Exchange program during an interview with former Mexican President Vicente Fox.
During the Tuesday broadcast, Fox discussed the global challenge of antibiotic resistance, particularly regarding hospital-acquired infections. He emphasized Steriwave as a non-antibiotic therapy for infection prevention that does not generate resistance, according to the company’s press release.
Fox, who was announced as Chair of the Light Against AMR Initiative on August 11, highlighted the potential role of light-activated antimicrobial technologies in addressing multidrug-resistant infections, especially in developing nations with limited healthcare access.
The Light Against AMR Initiative is a program co-sponsored by Ondine Biomedical and the International Photodynamic Association aimed at expanding light-based infection control technologies in emerging markets.
"We are pleased that Steriwave photodisinfection and the urgent issue of antimicrobial resistance were both spotlighted on CNBC’s Worldwide Exchange," said Dr. Nicolas Loebel, President and CTO of Ondine Biomedical, in the statement.
Ondine Biomedical describes itself as a life sciences company developing light-activated, non-antibiotic infection prevention therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.